Literature DB >> 19184289

Standardization for mass production of allogeneic cultured dermal substitute by measuring the amount of VEGF, bFGF, HGF, TGF-beta, and IL-8.

Akiko Hashimoto1, Yoshimitsu Kuroyanagi.   

Abstract

Fibroblasts were isolated from a piece of donated skin measuring about 1 x 1 cm and were proliferated over nine successive cultivations. Fibroblasts obtained from the fourth cultivation were cryopreserved in 10 cryotubes as master cells. Fibroblasts obtained from the fifth to ninth cultivations were cryopreserved in 49 cryotubes in total as working cells. At the end of each procedure in the fourth to eighth cultivations, about three-quarters of the proliferated fibroblasts were cryopreserved, and the remaining one-quarter were proliferated in the next cultivation. All fibroblasts obtained from the ninth (final) procedure were cryopreserved as the last working cells. Two cryotubes of the last cryopreserved working cells (ninth cultivation) were thawed and proliferated. Cultured dermal substitute (CDS) was prepared by performing ten successive cultivations. After each cultivation, about three-quarters of the resulting fibroblasts were used to prepare CDS, and the remaining one-quarter were proliferated in the next cultivation for 1 week. Finally, all fibroblasts produced by the tenth (final) procedure were used to prepare CDS. In each of the first to ninth cultivations for CDS preparation, the density of fibroblasts remained relatively constant, and the levels of cytokines, i.e., vascular endothelial growth factor, basic fibroblast growth factor, hepatocyte growth factor, transforming growth factor-beta 1, and interleukin-8 released from CDS remained relatively constant. In total, 47 sheets of CDS measuring 10 x 10 cm were prepared. The present findings indicate that about 1000 sheets of CDS measuring 10 x 10 cm can be prepared using all the working cells prepared from a piece of donated skin measuring 1 x 1 cm.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19184289     DOI: 10.1007/s10047-008-0436-1

Source DB:  PubMed          Journal:  J Artif Organs        ISSN: 1434-7229            Impact factor:   1.731


  22 in total

1.  Treatment of full-thickness skin defect with concomitant grafting of 6-fold extended mesh auto-skin and allogeneic cultured dermal substitute.

Authors:  Naohiro Kashiwa; Osamu Ito; Takeshige Ueda; Kentaro Kubo; Hiromichi Matsui; Yoshimitsu Kuroyanagi
Journal:  Artif Organs       Date:  2004-05       Impact factor: 3.094

2.  Intractable leg ulcers associated with antiphospholipid syndrome with stasis dermatitis: treatment with allogeneic cultured dermal substitute.

Authors:  Junko Nishimoto; Yasuyuki Amoh; Kenichi Tanabe; Nanako Niiyama; Kensei Katsuoka; Yoshimitsu Kuroyanagi
Journal:  Eur J Dermatol       Date:  2007-06-01       Impact factor: 3.328

3.  An allogeneic cultured dermal substitute suitable for treating intractable skin ulcers and large skin defects prior to autologous skin grafting: three case reports.

Authors:  Toshio Hasegawa; Yasushi Suga; Masayuki Mizoguchi; Shigenori Muramatsu; Yuki Mizuno; Hideoki Ogawa; Kentaro Kubo; Yoshimitsu Kuroyanagi
Journal:  J Dermatol       Date:  2005-09       Impact factor: 4.005

4.  Clinical study with allogeneic cultured dermal substitutes for chronic leg ulcers.

Authors:  Masao Yonezawa; Hideaki Tanizaki; Naoko Inoguchi; Masahide Ishida; Mayumi Katoh; Takao Tachibana; Yoshiki Miyachi; Kentaro Kubo; Yoshimitsu Kuroyanagi
Journal:  Int J Dermatol       Date:  2007-01       Impact factor: 2.736

5.  A study of cytokines released from fibroblasts in cultured dermal substitute.

Authors:  Kentaro Kubo; Yoshimitsu Kuroyanagi
Journal:  Artif Organs       Date:  2005-10       Impact factor: 3.094

6.  Spongy matrix of hyaluronic acid and collagen as a cultured dermal substitute: evaluation in an animal test.

Authors:  Kentaro Kubo; Yoshimitsu Kuroyanagi
Journal:  J Artif Organs       Date:  2003       Impact factor: 1.731

7.  Clinical evaluation of allogeneic cultured dermal substitutes for intractable skin ulcers after tumor resection.

Authors:  Yoichi Moroi; Shohei Fujita; Shuji Fukagawa; Toshihiko Mashino; Takako Goto; Teiichi Masuda; Kazunori Urabe; Kentaro Kubo; Hiromichi Matsui; Shizuko Kagawa; Yoshimitsu Kuroyanagi; Masutaka Furue
Journal:  Eur J Dermatol       Date:  2004 May-Jun       Impact factor: 3.328

8.  Digital gangrene associated with idiopathic hypereosinophilia: treatment with allogeneic cultured dermal substitute (CDS).

Authors:  Toshio Ohtani; Katsuyuki Okamoto; Chikako Kaminaka; Tomoh Kishi; Mikihisa Sakurane; Yuki Yamamoto; Koji Uede; Kentaro Kubo; Yoshimitsu Kuroyanagi; Fukumi Furukawa
Journal:  Eur J Dermatol       Date:  2004 May-Jun       Impact factor: 3.328

9.  Development of a cultured dermal substitute composed of a spongy matrix of hyaluronic acid and atelo-collagen combined with fibroblasts: cryopreservation.

Authors:  Kentaro Kubo; Yoshimitsu Kuroyanagi
Journal:  Artif Organs       Date:  2004-02       Impact factor: 3.094

10.  Hepatocyte growth factor may accelerate healing in chronic leg ulcers: a pilot study.

Authors:  F Nayeri; T Strömberg; M Larsson; L Brudin; C Söderström; P Forsberg
Journal:  J Dermatolog Treat       Date:  2002-06       Impact factor: 3.359

View more
  5 in total

Review 1.  Journal of Artificial Organs 2008: the year in review.

Authors:  Y Sawa; E Tatsumi; A Funakubo; T Horiuchi; K Iwasaki; A Kishida; T Masuzawa; K Matsuda; M Nishimura; T Nishimura; Y Tomizawa; T Yamaoka; H Watanabe
Journal:  J Artif Organs       Date:  2009-03-29       Impact factor: 1.731

2.  A case of lower-extremity deep burn wounds with periosteal necrosis successfully treated by use of allogenic cultured dermal substitute.

Authors:  Naoki Ohara; Shoji Mihara; Hiroyuki Nihara; Narihiro Akimoto; Naoki Madokoro; Mikio Kawai; Hideki Noda; Michihiro Hide; Yasuhiro Matsumoto; Yoshimitsu Kuroyanagi
Journal:  J Artif Organs       Date:  2010-03-27       Impact factor: 1.731

3.  Skin substitutes based on allogenic fibroblasts or keratinocytes for chronic wounds not responding to conventional therapy: a retrospective observational study.

Authors:  Giorgio Pajardi; Vicenzo Rapisarda; Francesco Somalvico; Andrea Scotti; Giulia Lo Russo; Francesco Ciancio; Arturo Sgrò; Manuela Nebuloni; Raffaele Allevi; Maria L Torre; Emilio Trabucchi; Mario Marazzi
Journal:  Int Wound J       Date:  2014-02-12       Impact factor: 3.315

4.  Treatment of intractable skin ulcers caused by vascular insufficiency with allogeneic cultured dermal substitute: a report of eight cases.

Authors:  Tomonori Taniguchi; Yasuyuki Amoh; Kenichi Tanabe; Kensei Katsuoka; Yoshimitsu Kuroyanagi
Journal:  J Artif Organs       Date:  2011-08-23       Impact factor: 1.731

5.  Clinical trial of allogeneic cultured dermal substitutes for intractable skin ulcers.

Authors:  Naoto Yamada; Eiju Uchinuma; Yoshimitsu Kuroyanagi
Journal:  J Artif Organs       Date:  2011-12-03       Impact factor: 1.731

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.